Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
BUSINESS
Chugai Renews Record Earnings in 2018 on New Drugs, Exports
Chugai Pharmaceutical delivered record sales and operating profit in 2018 as drug price cuts in April were more than offset by strong sales of new drugs including Hemlibra (emicizumab) and Tecentriq (atezolizumab) and exports to Roche, with one-off gains from…
To read the full story
Related Article
- Chugai Nets 40%-Plus Profit Rise, but Keeps 3-Year EPS Target; President Nixes Avastin Biosame
July 26, 2019
- Chugai Rings Up Record Q1 Earnings on Brisk New Drug Sales
April 25, 2019
- Chugai Plays It Safe with New 3-Year Plan on Consecutive Re-Pricing, Eyes 7-9% Annual EPS Growth
February 1, 2019
- Tecentriq, Hemlibra Get Off with a Bang, Clear 2018 Targets Already: Chugai
October 25, 2018
- Chugai Sees Solid Uptake for Tecentriq, Hemlibra but CEO Frets Pricing Stability
July 27, 2018
- Chugai Notches Up Record Earnings in 2017 on Bullish Exports, Milestones
February 2, 2018
BUSINESS
- Tepezza, Trodelvy, and More Drugs Now Available in Japan; Kisunla Due Out on Nov. 26
November 21, 2024
- MM Drug Talquetamab Filed in Japan: J&J
November 21, 2024
- Terumo Puts Brake on Supply of Anapeine Generics
November 21, 2024
- Otsuka Plans US Filing of IgA Nephropathy Drug in H1 2025
November 20, 2024
- 25 Japan Drug Makers See 50% Growth in Operating Profit on FX, Unprofitability Re-Pricing
November 20, 2024
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…